Women in Biotech
Thursday 24 September 2020
Our Women in Biotech continues in virtual format this September. Join us for an early evening event with networking and thought-provoking discussion.
The BIA’s Women in Biotech event series has been running for over 12 years and aims to connect, inspire, and support women across the sector.
AGENDA TBC - draft below
16.00 Sign in and table networking
16.20 Welcome from BIA and Bird & Bird
Jane Wall, Director of Business Development and Membership Services, BIA
Tbc, Bird & Bird
16.30 Discussion and Q&A
Chair: Jo Pisani, Strategic Advisor, non executive director and charity trustee
Jane Osbourn OBE, Chair, Mogrify
Anne Osbourn OBE, Project Leader, John Innes Centre
17.30 Networking at virtual tables
19:00 Event closes
We are excited to bring you this Women in Biotech event in virtual format.
You will be able to join us online to network and, similar to an in-person event, move from virtual table to table to mingle with other attendees. The platform we will be using also includes useful features which will allow you to message directly with other attendees and share LinkedIn details to connect. There is also a general chat for all attendees.
During the panel discussion you will be able to submit and vote on audience questions and we will try our best to cover everything in the time allocated.
What are the technical requirements to attend the virtual event?
- There is no software installation or download required.
- Please attend using a laptop or desktop computer with audio and video capabilities (webcam and microphone). The mobile or tablet views are still in the beta stage.
- You will need to use one of the supported browsers to have the best user experience:
Chrome, Safari, or Firefox.
- If you want to check the technical requirements in more detail, you can view their checklist here.
If your company has firewalls or browsing restrictions in place, please test your connection and liaise with your IT team in advance to ensure you are able to fully participate in the event.
After a 30 year career in industry and consulting, Jo is now focused on supporting charities, universities and business start-ups.
She is on the board of the UK Dementia Research Institute, The RSA Group and Findacure. She is also on the advisory boards for MedCity and the University of Birmingham. Prior to this she let PwC’s UK Pharmaceutical and Life Sciences practice and started her career with BP and GSK.
She is a passionate supporter of critical public health issues, such as tackling dementia and addressing anti-microbial resistance.
Dr Jane Osbourn OBE
Jane has over 30 years of experience in biologics discovery and development. Most recently, she was Vice President for R&D and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology.
Jane is a scientific leader in the field of antibody engineering, and has made a significant contribution to the discovery and development of 8 marketed drugs and over 40 clinical candidates. Jane is passionate about science education and the development of the UK biotech sector and has served as Chair of the Board of Directors of the BioIndustry Association for the past four years. She is currently a Director of Babraham Bioscience Technologies, and also a Director of Cambridge Enterprise. She was awarded Scrip’s Lifetime Achievement Award and an OBE in 2019 for services to drug discovery, development and biotechnology.
Anne Osbourn OBE
Anne Osbourn is a Project Leader at the John Innes Centre and Director of the Norwich Research Park Industrial Biotechnology Alliance. She is also an honorary professor at the University of East Anglia. Her research focuses on plant-derived natural products - function, synthesis, mechanisms of metabolic diversification and metabolic engineering. An important advance from the Osbourn laboratory has been the discovery that in plant genomes the genes needed to make particular natural products are often organised in clusters like ‘beads on a string’, a finding that has greatly accelerated our ability to find new pathways and chemistries of potential importance for the development of drugs and other useful compounds. She has established a synthetic biology platform based on transient plant expression that provides rapid access to previously inaccessible natural products and analogs at gram scale. Together these two step changes open up new routes to combine genomics and synthetic biology to synthesize and access previously inaccessible natural products and analogs for medicinal, agricultural and industrial applications. Anne has also developed and co-ordinates the Science, Art and Writing (SAW) Initiative, a cross-curricular science education outreach programme (www.sawtrust.org).
Thank you to our Women in Biotech series sponsor